• 1
    Hargraves MM. Discovery of the LE cell and its morphology. Mayo Clin Proc 1969; 44: 57999.
  • 2
    Emlen W, O'Neill L. Clinical significance of antinuclear antibodies: comparison of detection with immunofluorescence and enzyme-linked immunosorbent assays. Arthritis Rheum 1997; 40: 161218.
  • 3
    Lock RJ, Unsworth DJ. Antibodies to extractable nuclear antigens: has technological drift affected clinical interpretation? J Clin Pathol 2001; 54: 18790.
  • 4
    Swaak AJ, Huysen V, Smeenk RJ. Antinuclear antibodies in routine analysis: the relevance of putative assocations. Ann Rheum Dis 1993; 52: 1104.
  • 5
    Juby A, Johnston C, Davis P. Specificity, sensitivity and diagnostic predictive value of selected laboratory generated autoantibody profiles in patients with connective tissue diseases. J Rheumatol 1991; 18: 3548.
  • 6
    Fritzler MJ, Pauls JD, Kinsella TD, Bowen TJ. Antinuclear, anticytoplasmic, and anti-Sjögren's syndrome antigen A (SS-A/Ro) antibodies in female blood donors. Clin Immunol Immunopathol 1985; 36: 1208.
  • 7
    Anderson P. Correlation of smooth-muscle and nuclear antibodies in normal subjects. Clin Exp Immunol 1977; 27: 747.
  • 8
    Svec KH, Veit BC. Age-related antinuclear factors: immunologic characteristics and associated clinical aspects. Arthritis Rheum 1967; 10: 50916.
  • 9
    Tan EM, Smolen JS, McDougal JS, et al. A critical evaluation of enzyme immunoassays for detection of antinuclear autoantibodies of defined specificities. I. Precision, sensitivity, and specificity. Arthritis Rheum 1999; 42: 45564.
  • 10
    Maddison PJ, Skinner RP, Pereira RS, Black CM, Answell BM, Jayson MI, et al. Antinuclear antibodies in the relatives and spouses of patients with systemic sclerosis. Ann Rheum Dis 1986; 45: 7939.
  • 11
    Barnett AJ, McNeilage LJ. Antinuclear antibodies in patients with scleroderma and in their blood relatives. Ann Rheum Dis 1993; 52: 3658.
  • 12
    Harvey G, Black C, Maddison P, McHugh N. Characterization of antinuclear antibody reactivity in patients with systemic sclerosis and their relatives. J Rheumatol 1997; 24: 47784.
  • 13
    Pereira S, Black C, Welsh K, Ansell B, Jayson M, Maddison P, et al. Autoantibodies and immunogenetics in 30 patients with systemic sclerosis and their families. J Rheumatol 1987; 14: 7605.
  • 14
    Solheim BG, Larsen RA. Family studies in systemic lupus erythematosus. IV. Presence of antinuclear factors (ANFs) in the total populations of relatives and spouses, and the correlation to rheumatic disease. Acta Med Scand Suppl 1972; 543: 4353.
  • 15
    Valentini G, Improta RD, Resse M, Migliaresi S, Minucci PB, Tirri R, et al. Antinuclear antibodies in first-degree relatives of patients with polymyositis-dermatomyositis: analysis of the relationship with HLA haplotypes. Br J Rheumatol 1991; 30: 42932.
  • 16
    Weitzman RJ, Walker SE. Relation of titred peripheral pattern ANA to anti-DNA and disease activity in systemic lupus erythematosus. Ann Rheumatic Dis 1977; 36: 449.
  • 17
    Sulcebe G, Morcka K. Diagnostic and prognostic significance of different antinuclear antibodies in more than 1000 consecutive Albanian patients with rheumatic diseases. Clin Exp Rheumatol 1992; 10: 25561.
  • 18
    Davis P, Stein M, Ley H, Johnston C. Serological profiles in the connective tissue diseases in Zimbabwean patients. Ann Rheumatic Dis 1989; 48: 7376.
  • 19
    Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980; 23: 58190.
  • 20
    Chudwin DS, Ammann AJ, Cowan MJ, Wara DW. Significance of a positive antinuclear antibody test in a pediatric population. Am J Dis Child 1983; 137: 11036.
  • 21
    Calvo-Alen J, Alarcon GS, Burgard SL, Burst N, Bartolucci AA, Williams HJ. Systemic lupus erythematosus: predictors of its occurrence among a cohort of patients with early undifferentiated connective tissue disease: multivariate analyses and identification of risk factors. J Rheumatol 1996; 23: 46975.
  • 22
    Ginsburg WW, Conn DL, Bunch TW, McDuffie FC. Comparison of clinical and serologic markers in systemic lupus erythematosus and overlap syndrome: a review of 247 patients. J Rheumatol 1983; 10: 23541.
  • 23
    Rothfield NF, Rodnan GP. Serum antinuclear antibodies in progressive systemic sclerosis (scleroderma). Arthritis Rheum 1968; 11: 60717.
  • 24
    Arroyave CM, Giambrone MJ, Rich KC, Walaszek M. The frequency of antinuclear antibody (ANA) in children by use of mouse kidney (MK) and human epithelial cells (HEp-2) as substrates. J Allergy Clin Immunol 1988; 82: 7414.
  • 25
    Jonsson H, Nived O, Sturfelt G. The effect of age on clinical and serological manifestations in unselected patients with systemic lupus erythematosus. J Rheumatol 1988; 15: 5059.
  • 26
    Hochberg MC, Boyd RE, Ahearn JM, Arnett FC, Bias WB, Provost TT, et al. Systemic lupus erythematosus: a review of clinico-laboratory features and immunogenetic markers in 150 patients with emphasis on demographic subsets. Medicine 1985; 64: 28595.
  • 27
    Arnett FC, Bias WB, McLean RH, Engel M, Duvic M, Goldstein R, et al. Connective tissue disease in southeast Georgia: a community based study of immunogenetic markers and autoantibodies. J Rheumatol 1990; 7: 102935.
  • 28
    Schur PH, DeAngelis D, Jackson JM. Immunological detection of nucleic acids and antibodies to nucleic acids and nuclear antigens by counterimmunoelectrophoresis. Clin Exp Immunol 1974; 17: 20918.
  • 29
    Koh WH, Fong KY, Boey ML, Feng PH. Systemic lupus erythematosus in 61 Oriental males: a study of clinical and laboratory manifestations. Br J Rheumatol 1994; 33: 33942.
  • 30
    Nisengard RJ, Jablonska S, Chorzelski TP, Blaszcyk M, Jarret C, Beutner EH. Diagnosis of systemic lupus erythematosus. Importance of antinuclear antibody titers and peripheral staining patterns. Arch Dermatol 1975; 111: 1298300.
  • 31
    Mulli JC, Cruchaud A. Immunoreactivity to nuclear antigens in systemic lupus erythematosus with or without nephritis, and in other connective tissue diseases, with particular reference to the RNA-protein antigen. Int Arch Allergy Immunol 1977; 53: 27989.
  • 32
    Speransky AI, Ivanova MI, Rjazantceva TA, Piven VA, Bulanova TD. Antinuclear antibodies in lupus erythematosus and Sjögren's syndrome: clinical and immunological investigations. Scand J Rheumatol Suppl 1987; 67: 3943.
  • 33
    Chellingworth MC, Salmon M, Scott DL, Bacon PA. The significance of IgM antinuclear antinuclear antibody in rheumatoid arthritis and other connective tissue diseases. Rheumatol Int 1984; 4: 235.
  • 34
    Rooij DJ, Habets WJ, Stapel S, van de Putte LB, van Venrooij WJ. Clinical significance of antibodies against nuclear antigens as determined by immunoblotting. Scand J Rheumatol Suppl 1985; 56: 937.
  • 35
    Kallenberg CG, Wouda AA, The TH. Systemic involvement and immunologic findings in patients presenting with Raynaud's phenomenon. Am J Med 1980; 69: 67580.
  • 36
    Clegg DO, Williams HJ, Singer JZ, Steen VD, Schlegel S, Ziminski C. Early undifferentiated connective tissue disease. II. The frequency of circulating antinuclear antibodies in patients with early rheumatic diseases. J Rheumatol 1991; 18: 13403.
  • 37
    American College of Rheumatology Ad Hoc Committee on Immunologic Testing Guidelines. Guidelines for immunologic laboratory testing in the rheumatic diseases: an introduction. Arthritis Rheum (Arthritis Care Res) 2002; 47: 42933.
  • 38
    Catoggio LJ, Bernstein RM, Black CM, Hughes GR, Maddison PJ. Serological markers in progressive systemic sclerosis: clinical correlations. Ann Rheum Dis 1983; 42: 237.
  • 39
    Tan EM, Rodnan GP, Garcia I, Moroi Y, Fritzler MJ, Peebles C, et al. Diversity of antinuclear antibodies in progressive systemic sclerosis: anti-centromere antibody and its relationship to CREST syndrome. Arthritis Rheum 1980; 23: 61725.
  • 40
    Bulpitt KJ, Clements PJ, Lachenbruch PA, Paulus HE, Peter JB, Agopian MS, et al. Early undifferentiated connective tissue disease: III. Outcome and prognostic indicators in early scleroderma (systemic sclerosis). Ann Intern Med 1993; 118: 6029.
  • 41
    Cruz M, Mejia G, Lavalle C, Cortes JJ, Reyes PA. Antinuclear antibodies in scleroderma, mixed connective tissue disease and “primary” Raynaud's phenomenon. Clin Rheumatol 1988; 7: 806.
  • 42
    Giordano M, Valentini G, Migliaresi S, Picillo U, Vatti M. Different antibody patterns and different prognoses in patients with scleroderma with various extent of skin sclerosis. J Rheumatol 1986; 13: 9116.
  • 43
    Bruns M, Herrmann K, Haustein UF. Immunologic parameters in systemic sclerosis. Int J Dermatol 1994; 33: 2532.
  • 44
    Igarashi A, Takehara K, Soma Y, Kikuchi K, Ishibashi Y. Clinical significance of antinuclear antibodies in Japanese patients with systemic sclerosis. Dermatologica 1990; 180: 13640.
  • 45
    Picillo U, Migliaresi S, Marcialis MR, Ferruzzi AM, Tirri G. Clinical setting of patients with systemic sclerosis by serum autoantibodies. Clin Rheumatol 1997; 16: 37883.
  • 46
    Furst DE, Clements PJ, Saab M, Sterz MG, Paulus HE. Clinical and serological comparison of 17 chronic progressive systemic sclerosis (PSS) and 17 CREST syndrome patients matched for sex, age, and disease duration. Ann Rheum Dis 1984; 43: 794801.
  • 47
    Barnett AJ, McNeilage LJ. Antinuclear antibodies in patients with scleroderma (systemic sclerosis) and in their blood relatives and spouses. Ann Rheum Dis 1993; 52: 3658.
  • 48
    Kipnis RJ, Craft J, Hardin JA. The analysis of antinuclear and antinucleolar autoantibodies of scleroderma by radioimmunoprecipitation assays. Arthritis Rheum 1990; 33: 14317.
  • 49
    Maddison PJ, Skinner RP, Pereira RS, Black CM, Ansell BM, Jayson MI, et al. Antinuclear antibodies in the relatives and spouses of patients with systemic sclerosis. Ann Rheum Dis 1986; 45: 7939.
  • 50
    Aeschlimann A, Meyer O, Bourgeois P, Haim T, Belmatoug N, Palazzo E, et al. Anti-Scl-70 antibodies detected by immunoblotting in progressive systemic sclerosis: specificity and clinical correlations. Ann Rheum Dis 1989; 48: 9927.
  • 51
    Winkelstein A, Bernstein ML, Stevens MA, Rodnan GP, Medsger TA Jr, Dobson SA. Reduced T lymphoid colony growth in patients with progressive systemic sclerosis and rheumatoid arthritis. J Lab Clin Med 1982; 100: 2407.
  • 52
    Fritzler MJ, Kinsella TD. The CREST syndrome: a distinct serologic entity with anticentromere antibodies. Am J Med 1980; 69: 5206.
  • 53
    Takehara K, Moroi Y, Ishibashi Y. Antinuclear antibodies in the relatives of patients with systemic sclerosis. Br J Dermatol 1985; 112: 2333.
  • 54
    Sato S, Ihn H, Soma Y, Igarashi A, Tamaki T, Kikuchi K, et al. Antihistone antibodies in patients with localized scleroderma. Arthritis Rheum 1993; 36: 113741.
  • 55
    Love LA, Leff RL, Fraser DD, Targoff IN, Dalakas M, Plotz PH, et al. A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups. Medicine 1991; 70: 36074.
  • 56
    Valentini G, Improta RD, Resse M, Migliaresi S, Minucci PB, Tirri R, et al. Antinuclear antibodies in first-degree relatives of patients with polymyositis-dermatomyositis: analysis of the relationship with HLA haplotypes. Br J Rheumatol 1991; 30: 42932.
  • 57
    Holden DJ, Brownell AK, Fritzler MJ. Clinical and serologic features of patients with polymyositis or dermatomyositis. CMAJ 1985; 132: 64953.
  • 58
    Venables PJ, Mumford PA, Maini RN. Antibodies to nuclear antigens in polymyositis: relationship to autoimmune “overlap syndromes” and carcinoma. Ann Rheum Dis 1981; 40: 21723.
  • 59
    Reichlin M, Arnett FC. Multiplicity of antibodies in myositis sera. Arthritis Rheum 1984; 27: 11506.
  • 60
    Montecucco C, Ravelli A, Caporali R, Viola S, De Gennaro F, Albani S, et al. Autoantibodies in juvenile dermatomyositis. Clin Exp Rheumatol 1990; 8: 1936.
  • 61
    Fossaluzza V, De Vita S. Clinical differences between ANA/anti-DNA positive or negative primary Sjögren's syndrome. Clin Rheumatol 1992; 11: 3857.
  • 62
    Ben-Chetrit E, Fischel R, Rubinow A. Anti-SSA/Ro and anti-SSB/La antibodies in serum and saliva of patients with Sjögren's syndrome. Clin Rheumatol 1993; 12: 4714.
  • 63
    Rouquette-Gally AM, Boyeldieu D, Gluckman E, Abuaf N, Combrisson A. Autoimmunity in 28 patients after allogeneic bone marrow transplantation: comparison with Sjögren's syndrome and scleroderma. Br J Haematol 1987; 66: 457.
  • 64
    Alspaugh MA, Talal N, Tan EM. Differentiation and characterization of autoantibodies and their antigens in Sjögren's syndrome. Arthritis Rheum 1976; 19: 21622.
  • 65
    Pease CT, Shattles W, Charles PJ, Venables PJ, Maini RN. Clinical, serological, and HLA phenotype subsets in Sjögren's syndrome. Clin Exp Rheumatol 1989; 7: 18590.
  • 66
    Tishler M, Aharon A, Ehrenfeld M, Avni I, Bendet E, Bombardieri S, et al. Sjögren's syndrome in Israel: primary versus secondary disease. Clin Rheumatol 1994; 13: 43841.
  • 67
    Boire G, Menard HA, Gendron M, Lussier A, Myhal D. Rheumatoid arthritis: anti-Ro antibodies define a non-HLA-DR4 associated clinicoserological cluster. J Rheumatol 1993; 20: 165460.
  • 68
    Drosos AA, Tsiakou EK, Tsifetaki N, Politi EN, Siamopoulou-Mavridou A. Subgroups of primary Sjögren's syndrome: Sjögren's syndrome in male and paediatric Greek patients. Ann Rheum Dis 1997; 56: 3335.
  • 69
    Alexander EL, Arnett FC, Provost TT, Stevens MB. Sjögren's syndrome: association of anti-Ro (SS-A) antibodies with vasculitis, hematologic abnormalities, and serologic hyperreactivity. Ann Intern Med 1983; 98: 1559.
  • 70
    Molina R, Provost TT, Arnett FC, Bias WB, Hochberg MC, Wilson RW, Alexander EL. Primary Sjögren's syndrome in men: clinical, serologic, and immunogenetic features. Am J Med 1986; 80: 2331.
  • 71
    Forstot SL, Forstot JZ, Peebles CL, Tan EM. Serologic studies in patients with keratoconjunctivitis sicca. Arch Ophthalmol 1981; 99: 88890.
  • 72
    Chen ZY, Silver RM, Ainsworth SK, Dobson RL, Rust P, Maricq HR. Association between fluorescent antinuclear antibodies, capillary patterns, and clinical features in scleroderma spectrum disorders. Am J Med 1984; 77: 81222.
  • 73
    Sheiner NM, Small P. Isolated Raynaud's phenomenon—a benign disorder. Ann Allergy 1987; 58: 1147
  • 74
    Gerbracht DD, Steen VD, Ziegler GL, Medsger TA, Rodnan GP. Evolution of primary Raynaud's phenomenon (Raynaud's disease) to connective tissue disease. Arthritis Rheum 1985; 28: 8792.
  • 75
    Takehara K, Soma Y, Ishibashi Y. Early detection of scleroderma spectrum disorders in patients with Raynaud's phenomenon. Dermatologica 1991; 183: 1648.
  • 76
    Wollersheim H, Thien T, Hoet MH, Van Venrooy WJ. The diagnostic value of several immunological tests for anti-nuclear antibody in predicting the development of connective tissue disease in patients presenting with Raynaud's phenomenon. Eur J Clin Invest 1989; 19: 53541.
  • 77
    Kallenberg CG, Wouda AA, The TH. Systemic involvement and immunologic findings in patients presenting with Raynaud's phenomenon. Am J Med 1980; 69: 67580.
  • 78
    Luggen M, Belhorn L, Evans T, Fitzgerald O, Spencer-Green G. The evolution of Raynaud's phenomenon: a long-term prospective study. J Rheumatol 1995; 22: 222632.
  • 79
    Moore TL, Osborn TG, Weiss TD, Sheridan PW, Eisenwinter RK, Miller AV, et al. Autoantibodies in juvenile arthritis. Semin Arthritis Rheum 1984; 13: 32936.
  • 80
    Malleson PN, Fung MY, Petty RE, Mackinnon MJ, Schroeder ML. Autoantibodies in chronic arthritis of childhood: relations with each other and with histocompatibility antigens. Ann Rheum Dis 1992; 51: 13016.
  • 81
    Gabay C, Prieur AM, Meyer O. Occurrence of antiperinuclear, antikeratin, and anti-RA 33 antibodies in juvenile chronic arthritis. Ann Rheum Dis 1993; 52: 7859.
  • 82
    Schaller JG, Johnson GD, Holborow EJ, Ansell BM, Smiley WK. The association of antinuclear antibodies with the chronic iridocyclitis of juvenile rheumatoid arthritis (Still's disease). Arthritis Rheum 1974; 17: 40916
  • 83
    Rossen RD, Brewer EJ, Person DA, Templeton JW, Lidsky MD. Circulating immune complexes and antinuclear antibodies in juvenile rheumatoid arthritis. Arthritis Rheum 1977; 20: 148590.
  • 84
    Pauls JD, Silverman E, Laxer RM, Fritzler MJ. Antibodies to histones H1 and H5 in sera of patients with juvenile rheumatoid arthritis. Arthritis Rheum 1989; 32: 87783.
  • 85
    Malleson P, Petty RE, Fung M, Candido EP. Reactivity of antinuclear antibodies with histones and other antigens in juvenile rheumatoid arthritis. Arthritis Rheum 1989; 32: 91923.
  • 86
    Burlingame RW, Rubin RL, Rosenberg AM. Autoantibodies to chromatin components in juvenile rheumatoid arthritis. Arthritis Rheum 1993; 36: 83641.
  • 87
    Ostensen M, Fredriksen K, Kass E, Rekvig OP. Identification of antihistone antibodies in subsets of juvenile chronic arthritis. Ann Rheum Dis 1989; 48: 1147.
  • 88
    Donn RP, Thomson W, Pepper L, Carthy D, Farhan A, Ryder C, et al. Antinuclear antibodies in early onset pauciarticular juvenile chronic arthritis (JCA) are associated with HLA-DQB1*0603: a possible JCA-associated human leucocyte antigen haplotype. Br J Rheumatol 1995; 34: 4615.
  • 89
    Rosenberg AM, Hauta SA, Prokopchuk PA, Romanchuk KG. Studies on associations of antinuclear antibodies with antibodies to an uveitogenic peptide of retinal S antigen in children with uveitis. J Rheumatol 1996; 23: 3703.
  • 90
    Siamopoulou-Mavridou A, Mavridis AK, Terzoglou C, Filopoulou S, Athanasiadou S, Tzioufas AG. Autoantibodies in Greek juvenile chronic arthritis patients. Clin Exp Rheumatol 1991; 9: 64752.
  • 91
    Rosenberg AM, Romanchuk KG. Antinuclear antibodies in arthritic and nonarthritic children with uveitis. J Rheumatol 1990; 17: 601.
  • 92
    Rosenberg AM, Prokopchuk PA. Comparison of ANA testing in JRA using immunofluorescent and immunoenzyme assays on HEp-2 cells. J Rheumatol 1988; 15: 1489.
  • 93
    Szer W, Sierakowska H, Szer IS. Antinuclear antibody profile in juvenile rheumatoid arthritis. J Rheumatol 1991; 18: 4018.
  • 94
    Munthe E. Anti-IgG and antinuclear antibodies in juvenile rheumatoid arthritis. Scand J Rheumatol 1972; 1: 16170.
  • 95
    Osborn TG, Patel NJ, Moore TI, Zuckner J. Use of the HEp-2 cell substrate in the detection of antinuclear antibodies in juvenile rheumatoid arthritis. Arthritis Rheum 1984; 27: 12869.
  • 96
    Neuteboom GH, Hertzberger-ten Cate R, de Jong J, van den Brink HG, Feltkamp TE. Antibodies to a 15 kD nuclear antigen in patients with juvenile chronic arthritis and uveitis. Invest Ophthalmol Vis Sci 1992; 33: 165760.
  • 97
    Garcia-de la Torre I, Miranda-Mendez L. Studies of antinuclear antibodies in rheumatoid arthritis. J Rheumatol 1982; 9: 6036.
  • 98
    Adebajo AO, Charles PJ, Hazleman BL, Maini RN. Serological profile of rheumatoid arthritis in west Africa. Rheumatol Int 1993; 12: 2358.
  • 99
    Steven MM, Teh LG, Teh LS, Pullar T, Belch JJ, Lewis D, et al. Value of test for antinuclear antibodies in rheumatic diseases. Br Med J (Clin Res Ed) 1984; 288: 17245.
  • 100
    Ritchie RF. The clinical significance of titered antinuclear antibodies. Arthritis Rheum 1967; 10: 54452.
  • 101
    Dorsch CA, Gibbs CB, Stevens MB, Shulman LE. Significance of nuclear immunofluorescent patterns. Ann Rheum Dis 1969; 28: 3139.
  • 102
    Rubin RL, Bell SA, Burlingame RW. Autoantibodies associated with lupus induced by diverse drugs target a similar epitope in the (H2A-H2B)-DNA complex. J Clin Invest 1992; 90: 16573.
  • 103
    Blomgren SE, Condemi JJ, Bignall MC, Vaughan JH. Antinuclear antibody induced by procainamide: a prospective study. N Engl J Med 1969; 281: 646.
  • 104
    Wilson JD, Bullock JY, Booth RJ. Influence of prazosin on the development of antinuclear antibodies in hypertensive patients. Clinical Pharmacol Ther 1979; 26: 20912.
  • 105
    Cody RJ, Calabrese LH, Clough JD, Tarazi RC, Bravo EL. Development of antinuclear antibodies during acebutolol therapy. Clin Pharmacol Therap 1979; 25: 8005.
  • 106
    Whalley LJ, Roberts DF, Wentzel J, Watson KC. Antinuclear antibodies and histocompatibility antigens in patients on long-term lithium therapy. J Affect Disord 1981; 3: 12330.
  • 107
    Cetina JA, Fishbein E, Alarcon-Segovia D. Antinuclear antibodies and propylthiouracil therapy. JAMA 1972; 220: 1012.
  • 108
    Wilson JD. Antinuclear antibodies and cardiovascular drugs. Drugs 1980; 19: 292305.
  • 109
    Alarcon-Segovia D, Fishbein E, Reyes PA, Dies H, Shwadsky S. Antinuclear antibodies in patients on anticonvulsant therapy. Clin Exp Immunol 1995; 12: 3947.
  • 110
    Quismorio FP, Bjarnason DF, Kiely WF, Dubois EL, Friou GJ. Antinuclear antibodies in chronic psychotic patients treated with chlorpromazine. Am J Psychiatry 1975; 132: 12046.
  • 111
    Sharp GC, Irvin WS, Tan EM, Gould RG, Holman HR. Mixed connective tissue disease—an apparently distinct rheumatic disease syndrome associated with a specific antibody to an extractable nuclear antigen (ENA). Am J Med 1972; 52: 14859.
  • 112
    Hameenkorpi R, Ruuska P, Forsberg S, Tiilikainen R, Makitalo R, Hakala M. More evidence of distinctive features of mixed connective tissue disease. Scand J Rheumatol 1993; 22: 638.
  • 113
    Frandsen PB, Kriegbaum NJ, Ullman S, Hoier-Madsen M, Wiik A, Halberg P. Follow-up of 151 patients with high-titer U1RNP antibodies. Clin Rheumatol 1996; 15: 25460.
  • 114
    Cruz M, Mejia G, Lavalle C, Cortes JJ, Reyes PA. Antinuclear antibodies in scleroderma, mixed connective tissue disease and “primary” Raynaud's phenomenon. Clin Rheumatol 1988; 7: 806.
  • 115
    Houtman PM, Kallenberg CG, Limburg PC, van Leeuwen MA, van Rijswijk MH. The TH fluctuations in anti-nRNP levels in patients with mixed connective tissue disease are related to disease activity as part of a polyclonal B cell response. Ann Rheum Dis 1986; 45: 8008.
  • 116
    Clifford BD, Donahue D, Smith L, Cable E, Luttig B, Manns M, et al. High prevalence of serological markers of autoimmunity in patients with chronic hepatitis C. Hepatology 1995; 21: 6139.
  • 117
    Bayraktar Y, Bayraktar M, Gurakar A, Hassanein TI, Van Thiel DH. A comparison of the prevalence of autoantibodies in individuals with chronic hepatitis C and those with autoimmune hepatitis: the role of interferon in the development of autoimmune diseases. Hepato-gastroenterology 1997; 44: 41725.
  • 118
    Imai H, Nakano Y, Kiyosawa K, Tan EM. Increasing titers and changing specificities of antinuclear antibodies in patients with chronic liver disease who develop hepatocellular carcinoma. Cancer 1993; 71: 2635.
  • 119
    Covini G, von Muhlen CA, Pacchetti S, Colombo M, Chan EK, Tan EM. Diversity of antinuclear antibody responses in hepatocellular carcinoma. J Hepatol 1997; 26: 125565.
  • 120
    Bernstein RM, Neuberger JM, Bunn CC, Callender ME, Hughes GR, Williams R. Diversity of autoantibodies in primary biliary cirrhosis and chronic active hepatitis. Clin Exp Immunol 1984; 55: 55360.
  • 121
    Dore-Duffy P, Donaldson JO, Rothman BL, Zurier RB. Antinuclear antibodies in multiple sclerosis. Arch Neurol 1982; 39: 5046.
  • 122
    Collard RC, Koehler RP, Mattson DH. Frequency and significance of antinuclear antibodies in multiple sclerosis. Neurology 1997; 49: 85761.
  • 123
    Singh VK. Detection of antinuclear antibody in the serum of patients with multiple sclerosis. Immunol Lett 1982; 4: 3179.
  • 124
    Kurata Y, Miyagawa S, Kosugi S, Kashiwagi H, Honda S, Mizutani H, et al. High-titer antinuclear antibodies, anti-SSA/Ro antibodies and anti-nuclear RNP antibodies in patients with idiopathic thrombocytopenic purpura. Thromb Haemost 1994; 71: 1847.
  • 125
    Anderson MJ, Peebles CL, McMillan R, Curd JG. Fluorescent antinuclear antibodies and anti-SS-A/Ro in patients with immune thrombocytopenia subsequently developing systemic lupus erythematosus. Ann Intern Med 1985; 103: 54850.
  • 126
    Panzer S, Penner E, Graninger W, Schulz E, Smolen JS. Antinuclear antibodies in patients with chronic idiopathic autoimmune thrombocytopenia followed 2–30 years. Am J Hematol 1989; 32: 1003.
  • 127
    Inamo Y, Harada K. Antinuclear antibody positivity in pediatric patients with autoimmune thyroid disease. J Rheumatol 1997; 24: 5768.
  • 128
    Petri M, Karlson EW, Cooper DS, Ladenson PW. Autoantibody tests in autoimmune thyroid disease: a case-control study. J Rheumatol 1991; 18: 152931.
  • 129
    Baethge BA, Levine SN, Wolf RE. Antibodies to nuclear antigens in Graves'disease. J Clin Endocrinol Metab 1988; 66: 4858.
  • 130
    Morita S, Arima T, Matsuda M. Prevalence of nonthyroid specific autoantibodies in autoimmune thyroid diseases. J Clin Endocrinol Metab 1995; 80: 12036.
  • 131
    Evans AW, Woodrow JC, McDougall CD, Chew AR, Evans RW. Antibodies in the families of thyrotoxic patients. Lancet 1967; 1: 63741.
  • 132
    Smart PA, Waylonis GW, Hackshaw KV. Immunologic profile of patients with fibromyalgia. Am J Phys Med Rehabil 1997; 76: 2314.
  • 133
    Silverman S, Gluck O, Silver D, Tesser J, Wallace D, Neumann K, et al. The prevalence of autoantibodies in symptomatic and asymptomatic patients with breast implants and patients with fibromyalgia. Curr Top Microbiol Immunol 1996; 210: 31722.
  • 134
    Dinerman H, Goldenberg DL, Felson DT. A prospective evaluation of 118 patients with the fibromyalgia syndrome: prevalence of Raynaud's phenomenon, sicca symptoms, ANA, low complement, and Ig deposition at the dermal-epidermal junction. J Rheumatol 1986; 13: 36873.
  • 135
    Yunus MB, Hussey FX, Aldag JC. Antinuclear antibodies and connective tissue disease features in fibromyalgia syndrome: a controlled study. J Rheumatol 1993; 20: 155760.